Non-Regulatory

June 15, 2013

Interim Report – January to March 2013

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™,...

Read more

Non-Regulatory

June 5, 2013

Affibody AB and AbClon enter into a License Agreement regarding the Affibody® Technology

Affibody AB and AbClon Inc. have signed a License Agreement regarding the use of Affibody’s proprietary technology platforms: Affibody® molecules and AlbumodTM for use in combination with AbClon’s proprietary...

Read more

Non-Regulatory

May 31, 2013

Kallelse till årsstämma

Aktieägarna i Affibody Holding AB (publ) kallas härmed till årsstämma fredagen den 28 juni 2013 kl 10.00 i bolagets lokaler, Gunnar Asplunds allé 24, Solna.

Read more

Non-Regulatory

May 22, 2013

Affibody AB and Daewoong Pharmaceutical Co., Ltd. enter into a License Agreement regarding the Albumod™ platform

Solna, Sweden, May 22, 2013. Affibody is pleased to announce a collaboration with Daewoong Pharmaceutical Co., Ltd.

Read more

Non-Regulatory

May 22, 2013

Affibody AB receives SwedenBIO award 2013

Solna, Sweden, May 22, 2013. Affibody wins SwedenBIO Award 2013 for its unique business model.

Read more

Non-Regulatory

April 30, 2013

First Patient Included in PET Imaging Study of HER2 Expression in Metastatic Breast Cancer

Solna, Sweden, April 30, 2013. Affibody is pleased to announce that the first patient has been enrolled in a clinical study to evaluate ABY-025 for PET imaging of HER2...

Read more

Non-Regulatory

February 15, 2013

Year-End Report 2012

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM,...

Read more

Non-Regulatory

November 1, 2012

Interim Report – January to Sept 2012

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM,...

Read more

Non-Regulatory

August 7, 2012

Interim Report – January to June 2012

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and AlbumodTM,...

Read more